An interventional study of the spot stent(ZENFLEX ® Pinto) system and the bare stent( Everflex) system in Peripheral Artery Disease, sponsored by Zhejiang Zylox Medical Device Co., Ltd.. Status unknown at 12 sites in China. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-09-30.
Sponsored by Zhejiang Zylox Medical Device Co., Ltd. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 80 studies in Peripheral Arterial Disease with a site in China — 32 open to participants now, 34 under way, 4 of them phase 3. Peripheral Arterial Disease · China.
Among the 80 studies in Peripheral Arterial Disease with a site in China, this one is the 16th largest by planned enrollment of the 53 interventional ones that give a count, is one of 8 that started in 2022, is one of 34 with no phase, and was the 47th registered.
1,378 studies on the registry are indexed under Peripheral Arterial Disease; 276 are open to participants now.
Browse Peripheral Arterial Disease studies →32 of the 80 studies in Peripheral Arterial Disease with a site in China are open now. Recruiting first, the newest first:
Peking University First Hospital · Sites in China
Ages 18–100 · Healthy volunteers
Eli Lilly and Company · Sites in China, United States, Argentina and 15 more countries
Ages 18+
Second Affiliated Hospital of Nanchang University · Sites in China
Ages 18+
Sirius Therapeutics Co., Ltd. · Sites in China
Ages 18–75
Liyuan Hospital of Tongji Medical College, Huazhong University of Science and Technology · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 193 Peripheral Arterial Disease studies recruiting now, 139 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
80 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 5 · Phase 3 11 · Phase 4 1
First in 2008; this study’s year is marked. 8 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 224 is above the median of 70 across 927 interventional studies indexed under Peripheral Arterial Disease.
Median enrollment 167 across the 53 interventional studies, 254 across the 27 observational. Of the 25 that completed or were terminated, 5 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
40 of 80 have an industry lead sponsor. The 10 most frequent:
Zhejiang Zylox Medical Device Co., Ltd. is the lead sponsor of 13 studies on the registry; 2 are open to participants now.
Zhejiang Zylox Medical Device Co., Ltd. has 8 studies filed under Peripheral Arterial Disease — fewer than ten, so there is no comparison to draw.
10 of the studies in Peripheral Arterial Disease with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06539689FrontAce Scientific Co., LtdA Trail of Sperstent® Used for Residual Lesions of Femoropopliteal Arteries | 2026-12-04 |
| NCT07397390The First Affiliated Hospital of Dalian Medical Universityan Observational Study Evaluting the Effectiveness and Safety of DKutting LL Noval Scoring Balloon Angioplasty for Vessel Preparation Facilitated by IVUS on the Lower Limb Ischemia Patients With Calcified Lesions | 2026-12-30 |
| NCT07602634Zhijun BaoRadiomics Features Predicting Outcomes of PAD | 2026-12-31 |
| NCT03791970Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityStents Post-dilation With DCB or POBA in Femoropopliteal Arteries | 2026-12-31 |
| NCT07860138Fudan UniversityHemodynamic Characteristics of Peripheral Arterial Disease Using Computational Fluid Dynamics | 2027-01 |
Add all 10 to your calendar (.ics) → With an account.
Among the 80 studies in Peripheral Arterial Disease with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a prospective, multicenter, randomized controlled trail using spot stenting to treat lower extremity post-angioplasty dissection.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
subjects using the spot stent(ZENFLEX ® Pinto) system
Device: the spot stent(ZENFLEX ® Pinto) system
subjects using the bare stent(Everflex) system
Device: the bare stent( Everflex) system
the spot stent(ZENFLEX ® Pinto) system、Color Doppler Ultrasonography (CDU) imaging、Dual Fluoroscopic Imaging、Digital subtraction angiography(DSA)
the bare stent( Everflex) system、Color Doppler Ultrasonography (CDU) imaging、Dual Fluoroscopic Imaging、Digital subtraction angiography(DSA)
primary patency rate at 12 months after operation
Time frame: 12 months
success rate of the device
Time frame: Intraoperation
success rate of the technique
Time frame: post operation
rate of CD-TLR
Time frame: 6 months,12 months
ABI
Time frame: post operation, 6 months,12 months
Rutherford classification
Time frame: post operation, 6 months,12 months
the incidence of major adverse events
Time frame: 30 days, 6 months,12 months
the rate of target limb major amputation
Time frame: 30 days, 6 months,12 months
the incidence of adverse events
Time frame: Intraoperation, post operation, 30 days, 6 months,12 months
the incidence of SAE
Time frame: Intraoperation, post operation, 30 days, 6 months,12 months
the rate of device defect
Time frame: Intraoperation, 12 months
Start is estimated for Nov 2022; primary completion for Feb 2024, 15 months later.
Of 125 industry-sponsored interventional studies with no phase under Peripheral Arterial Disease, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 45. This study's planned 15 months is below that.
Counting every sponsor, half of 386 studies reached it within 31 months; a quarter within 17 and three quarters within 55.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Zhejiang Zylox Medical Device Co., Ltd.